Literature DB >> 32855524

miR-21a in exosomes from Lewis lung carcinoma cells accelerates tumor growth through targeting PDCD4 to enhance expansion of myeloid-derived suppressor cells.

Xingju Zhang1,2, Fei Li3, Ying Tang1,2, Qinglan Ren4, Bin Xiao5, Ying Wan6, Shan Jiang7.   

Abstract

In patients with lung cancer, myeloid-derived suppressor cells (MDSCs) have been reported to be significantly increased. Tumor-derived exosomes (TDEs) from various cancers played a critical role in MDSC induction. However, studies on the molecular mechanism underlying MDSC expansion induced by exosomes from lung cancer cells are still limited. In this study, we demonstrated that LLC-Exo accelerated tumor growth along with a significant accumulation of MDSCs in mouse tumor model. miRNA profiling showed that miR-21a was enriched in LLC-Exo. The depletion of miR-21a in LLC-Exo leads to the loss of their ability to induce MDSC expansion. Further results showed that miR-21a of LLC-Exo induced MDSC expansion via downregulation of the programmed cell death protein 4 (PDCD4) protein. The results of gain-and loss-of-function experiments validated that PDCD4 function as a critical inhibitor to negatively regulate expansion of MDSCs via inhibition Il-6 production in bone marrow cells. In addition, our data showed that exosomes derived from human lung cancer cell lines expressing miR-21a, also induced expansion of MDSCs in human CD14+ monocytes in vitro. Overall, our results demonstrated that miR-21a enriched in lung carcinoma cell-derived exosomes could promote functional expansion of MDSCs through targeting PDCD4.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32855524     DOI: 10.1038/s41388-020-01406-9

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  77 in total

Review 1.  Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.

Authors:  Augusto C Ochoa; Arnold H Zea; Claudia Hernandez; Paulo C Rodriguez
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

2.  Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma.

Authors:  M K Brimnes; A J Vangsted; L M Knudsen; P Gimsing; A O Gang; H E Johnsen; I M Svane
Journal:  Scand J Immunol       Date:  2010-12       Impact factor: 3.487

3.  Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma.

Authors:  X-K Yuan; X-K Zhao; Y-C Xia; X Zhu; P Xiao
Journal:  J Int Med Res       Date:  2011       Impact factor: 1.671

Review 4.  Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.

Authors:  Neha Kamran; Mayuri Chandran; Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2016-10-21       Impact factor: 3.969

Review 5.  Myeloid derived-suppressor cells: their role in cancer and obesity.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Curr Opin Immunol       Date:  2018-03-13       Impact factor: 7.486

6.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

Review 7.  Myeloid-derived suppressor cells: linking inflammation and cancer.

Authors:  Suzanne Ostrand-Rosenberg; Pratima Sinha
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

Review 8.  Myeloid-Derived Suppressor Cells in Cancers and Inflammatory Diseases: Angel or Demon?

Authors:  Z Su; P Ni; C Zhou; J Wang
Journal:  Scand J Immunol       Date:  2016-11       Impact factor: 3.487

Review 9.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

10.  Visualization and quantification of in vivo homing kinetics of myeloid-derived suppressor cells in primary and metastatic cancer.

Authors:  Sabrina H L Hoffmann; Dorothea I Reck; Andreas Maurer; Birgit Fehrenbacher; Jaclyn E Sceneay; Marilena Poxleitner; Hasan H Öz; Walter Ehrlichmann; Gerald Reischl; Kerstin Fuchs; Martin Schaller; Dominik Hartl; Manfred Kneilling; Andreas Möller; Bernd J Pichler; Christoph M Griessinger
Journal:  Theranostics       Date:  2019-08-12       Impact factor: 11.556

View more
  8 in total

Review 1.  Emerging role of exosomes in cancer progression and tumor microenvironment remodeling.

Authors:  Mahshid Deldar Abad Paskeh; Maliheh Entezari; Sepideh Mirzaei; Amirhossein Zabolian; Hossein Saleki; Mohamad Javad Naghdi; Sina Sabet; Mohammad Amin Khoshbakht; Mehrdad Hashemi; Kiavash Hushmandi; Gautam Sethi; Ali Zarrabi; Alan Prem Kumar; Shing Cheng Tan; Marios Papadakis; Athanasios Alexiou; Md Asiful Islam; Ebrahim Mostafavi; Milad Ashrafizadeh
Journal:  J Hematol Oncol       Date:  2022-06-28       Impact factor: 23.168

Review 2.  Interaction Between microRNAs and Myeloid-Derived Suppressor Cells in Tumor Microenvironment.

Authors:  Lifei Liang; Xiaoqing Xu; Jiawei Li; Cheng Yang
Journal:  Front Immunol       Date:  2022-05-11       Impact factor: 8.786

Review 3.  Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers.

Authors:  Seiji Mabuchi; Tomoyuki Sasano
Journal:  Cells       Date:  2021-04-30       Impact factor: 6.600

Review 4.  The roles of exosomal immune checkpoint proteins in tumors.

Authors:  Cheng Xing; Heng Li; Rui-Juan Li; Le Yin; Hui-Fang Zhang; Zi-Neng Huang; Zhao Cheng; Ji Li; Zhi-Hua Wang; Hong-Ling Peng
Journal:  Mil Med Res       Date:  2021-11-08

Review 5.  Tumor-derived exosomes: immune properties and clinical application in lung cancer.

Authors:  Jing Wu; Suyao Li; Pengfei Zhang
Journal:  Cancer Drug Resist       Date:  2022-02-08

Review 6.  Emerging function and clinical significance of extracellular vesicle noncoding RNAs in lung cancer.

Authors:  Chan Shan; Yan Liang; Hongjing Cai; Fei Wang; Xinzhe Chen; Qikun Yin; Kun Wang; Yin Wang
Journal:  Mol Ther Oncolytics       Date:  2022-02-20       Impact factor: 7.200

Review 7.  MicroRNAs/LncRNAs Modulate MDSCs in Tumor Microenvironment.

Authors:  Xiaocui Liu; Shang Zhao; Hongshu Sui; Hui Liu; Minhua Yao; Yanping Su; Peng Qu
Journal:  Front Oncol       Date:  2022-03-14       Impact factor: 6.244

Review 8.  Myeloid Responses to Extracellular Vesicles in Health and Disease.

Authors:  Priya Makhijani; Tracy L McGaha
Journal:  Front Immunol       Date:  2022-03-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.